Empagliflozin (SGLT2 inhibitor)

metabolic glycemic

Approved medicine for another condition in 8 of 9 markets tracked; in clinical trials in 1.

1 randomized trial (7,020 people, 3 years). It improved its main endpoint, a count of deaths or new disease.

Evidence map

each mark is a study; size shows participants; hover, tap or focus for details

main endpoints improvedno effectworsenedmixedobservationalanother intervention, contextsize not reported

Higher rows are closer to a person taking this. A case that rests only on the lower rows rests on animals or cells.

What each study measured

outlined square: the main (primary) endpoint

Harms reported

human studies

Where it is available

by regulator; select a market for its source

If you are tracking this yourself

measures the human studies used, by how repeatable they are

Repeatability is whether the same person measured twice gets the same number. It is not statistical significance. It informs study or protocol design only, never advice for a person.

What would change this picture

each study's own statement

Trials under way

Every study (10)

T8 Zinman 2015 Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes doi:10.1056/NEJMoa1504720
T5 Htoo 2022 Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics doi:10.1001/jamanetworkopen.2022.37606
T5 Langslet 2024 Empagliflozin Use Is Associated With Lower Risk of All‐Cause Mortality, Hospitalization for Heart Failure, and End‐Stage Renal Disease Compared to DPP‐4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study doi:10.1155/2024/6142211
T5 Nyström 2022 Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase‐4 inhibitors: Real world evidence from the Nordic EMPRISE study doi:10.1111/dom.14870
T3 Obaid 2024 Evaluation of empagliflozin efficacy as a promising anti-aging treatment in mice: In-vivo study doi:10.3897/pharmacia.71.e116184
T3 Shi 2024 Empagliflozin protects against heart failure with preserved ejection fraction partly by inhibiting the senescence-associated STAT1-STING axis doi:10.1186/s12933-024-02366-0
TX Guthrie 2016 Empagliflozin Reduces Cardiovascular Events and Mortality in Type 2 Diabetes doi:10.1080/00325481.2016.1174566
TX Sarafidis 2016 Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (correspondence) doi:10.1056/NEJMc1600827
TX Kaul 2016 Is the Mortality Benefit With Empagliflozin in Type 2 Diabetes Mellitus Too Good To Be True? doi:10.1161/CIRCULATIONAHA.116.022537
TX Al-Mahdawi 2026 Mechanistic intersections of empagliflozin and nebivolol in aging-associated redox and inflammatory pathways doi:10.3389/fphar.2026.1842207